Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential CD19 and CD20 CAR-T for B-cell Lymphoma
NCT03207178Phase 2Unknown
- Sponsor
- Shanghai Longyao Biotechnology Co., Ltd.
- Start
- Mar 2017
- Primary completion
- Feb 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of MB-CART20.1 in B cell lymphoma, sponsored by Shanghai Longyao Biotechnology Co., Ltd.. Status: unknown.
02
Drugs
MB-CART20.1
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03207178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207178.